Vanguard Group Inc Kamada LTD Transaction History

Vanguard Group Inc

$4.96 Trillion
Q1 2024

A detailed history of Vanguard Group Inc transactions in Kamada LTD stock. As of the latest transaction made, Vanguard Group Inc holds 1,325,026 shares of KMDA stock, worth $6.69 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,325,026

Previous 1,224,226 8.23%

Holding current value

$6.69 Million

Previous $7.49 Million 0.79%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$5.58 - $6.42 $562,464 - $647,136	100,800 Added 8.23%	1,325,026 $7.43 Million
Q4 2023 Feb 14, 2024	BUY	$4.14 - $6.22 $838,590 - $1.26 Million	202,558 Added 19.83%	1,224,226 $7.49 Million
Q3 2023 Nov 14, 2023	BUY	$4.86 - $5.83 $71,077 - $85,263	14,625 Added 1.45%	1,021,668 $5.46 Million
Q2 2023 Aug 14, 2023	BUY	$4.48 - $5.53 $43,563 - $53,773	9,724 Added 0.98%	1,007,043 $5.32 Million
Q1 2023 May 15, 2023	BUY	$4.12 - $5.25 $14,300 - $18,222	3,471 Added 0.35%	997,319 $4.63 Million

Q4 2022 Feb 10, 2023	BUY	$3.79 - $4.7 $489,133 - $606,577	129,059 Added 14.92%	993,848 $3.99 Million
Q3 2022 Nov 14, 2022	BUY	$4.45 - $5.43 $261,237 - $318,768	58,705 Added 7.28%	864,789 $3.9 Million
Q2 2022 Aug 12, 2022	BUY	$4.22 - $5.85 $112,391 - $155,803	26,633 Added 3.42%	806,084 $3.64 Million
Q1 2022 May 13, 2022	BUY	$5.43 - $6.81 $129,060 - $161,860	23,768 Added 3.15%	779,451 $4.3 Million
Q4 2021 Feb 14, 2022	BUY	$5.21 - $6.82 $2,063 - $2,700	396 Added 0.05%	755,683 $4.97 Million
Q2 2021 Aug 13, 2021	BUY	$5.67 - $6.33 $4.28 Million - $4.78 Million	755,287 New	755,287 $4.4 Million

Others Institutions Holding KMDA

# of Institutions

Shares Held

5.67M

Call Options Held

300

Put Options Held

151K

View Full List

About KAMADA LTD

Ticker KMDA
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 44,800,500
Market Cap $226M
Description
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytop...

More about KMDA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Kamada LTD Transaction History